Nerve stimulation device for restless legs syndrome during pregnancy
Tests a leg nerve stimulation device for restless legs syndrome in pregnant women.
Key facts
- Who runs it
- Rhode Island Hospital
- Where
- Providence, United StatesSee the site
- Trial code
- Registry title
- Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 15 Oct 2025
- Planned end
- 31 Oct 2026
- Type of study
- Interventional
- Treatments tested
- Peroneal Nerve Stimulation (PNS) Device
- Record updated
- 12 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with Restless Legs Syndrome (RLS). They will test a leg nerve stimulation device, TOMAC™, at home for 8 weeks.
- Age
- 18 years and older
- Sex
- Female
- Disease stage
- Pregnant between 21 and 26 weeks at enrollment, with one baby and no known problems in the baby. RLS must be diagnosed by IRLSSG criteria and confirmed by a sleep medicine specialist.
- Earlier treatment
- You cannot join if you have used the study device or any nerve stimulation device for RLS before.
Main reasons for not taking part
- Past preterm labor, or known problems found in the baby
- Epilepsy or past seizures, nerve or muscle disorders affecting balance or walking, or severe nerve damage in the lower legs
- Past deep vein thrombosis (blood clot in a deep vein) or blood flow problems that rule out the device
- Active medical implants such as pacemakers, or being on dialysis
- Severe untreated other sleep disorders, or severe mental health conditions
This trial only enrols pregnant participants. The registry sentence this rests on: * Pregnant individuals between 21 and 26 weeks' gestation at enrollment
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Age ≥18 years
- Pregnant individuals between 21 and 26 weeks' gestation at enrollment
- Singleton pregnancy without known fetal anomalies
- Confirmed clinical diagnosis of Restless Legs Syndrome (RLS) according to International Restless Legs Syndrome Study Group (IRLSSG) criteria, confirmed by a sleep medicine specialist to exclude RLS mimics
- Able and willing to provide informed consent
- Able and willing to comply with study procedures, including device usage, questionnaires, adherence diaries, and follow-up assessments up to 3 months postpartum
Who cannot take part
- Known fetal anomalies identified prior to enrollment; Neurological and neuromuscular disorders:
- Prior use of the study device or any neurostimulation device for RLS treatment
- History of preterm labor
- Pre-existing neuromuscular disorders affecting balance or gait
- Epilepsy or history of seizures; Cardiovascular and circulatory conditions:
- History of deep vein thrombosis (DVT)
- Circulatory conditions contraindicating peroneal nerve stimulation (PNS) device use; Dermatological conditions:
- Skin conditions at device application sites
- Known allergy to device materials; Other sleep disorders:
- Inadequately treated severe primary sleep disorders other than RLS (e.g., untreated severe sleep apnea, severe insomnia unrelated to RLS); Device and treatment experience exclusions (based on RESTFUL trial criteria):
- Presence of active medical implants (e.g., pacemakers, spinal cord stimulators); Other medical conditions:
- Severe psychiatric conditions (e.g., bipolar disorder, psychosis, severe anxiety or depression) that may interfere with adherence or accurate symptom reporting
- Any condition deemed by investigators to pose safety risks or impede participation; Other exclusions:
- Pregnancy-related:
- Severe peripheral neuropathy involving the lower legs
- Participants undergoing dialysis treatment
- Unable or unwilling to operate the device safely and independently
- Unable to participate reliably in follow-up assessments or complete self-reported diaries
Where in United States
- Rhode Island HospitalProvidence, United StatesContact: Vesna Buntak, MDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use.
Read full original descriptionShow less
The main questions the study aims to answer are:
Is TOMAC™ PNS a feasible and acceptable intervention for RLS in pregnant individuals? Are there any maternal, fetal, or neonatal safety concerns with PNS use during pregnancy? What are the patterns of adherence, tolerance, and usability of the TOMAC™ device in this population?
Participants will:
Use a non-invasive TOMAC™ peroneal nerve stimulator during 30-minute sessions as needed, for 8 weeks.
Complete questionnaires assessing feasibility, acceptability, symptom severity, and sleep quality (including AIM, IAM, FIM, IRLS, PGI-I, PSQI, ESS, FOSQ, and MOS-II).
Wear an actigraphy monitor to collect objective sleep data at baseline and at 4 weeks.
Attend scheduled follow-up visits and phone check-ins for maternal vital signs, uterine contraction and fetal monitoring, and neonatal outcome assessment.
This is a prospective, open-label, single-arm pilot study enrolling 15 pregnant participants between 21 and 26 weeks' gestation. Findings will provide the first dataset on the feasibility, acceptability, and safety of TOMAC™ PNS in pregnancy and inform the design of a future randomized controlled trial.
The group in the trial
- TOMAC™ Peroneal Nerve StimulationTreatment being tested
Participants will receive TOMAC™ peroneal nerve stimulation (PNS) therapy for Restless Legs Syndrome (RLS) during pregnancy. Following a supervised in-clinic titration session with uterine contraction and fetal monitoring at ≥28 weeks' gestation, participants will use the device at home for 8 weeks. Each therapy session lasts 30 minutes and can be performed as many times as needed daily, prioritizing periods of high symptom burden or before bedtime. Outcomes include feasibility, acceptability, adherence and maternal-fetal safety.
Treatment: Peroneal Nerve Stimulation (PNS) Device
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PENS-P: Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome (RLS)
- Plain-language title
- Nerve stimulation device for restless legs syndrome during pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2025